Recent Updates
Recently added Catalysts

BMS-986485

Phase 1

Undisclosed | Small molecule | Other |Bristol-Myers Squibb Company|Trials Updated: Oct 21, 2026

BMS-986485 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLEDDMC
Total Trials1
Total Enrollment50

FDA Designations

No designations recorded

BMS-986485 clinical trials

BMS-986485 · 1 trial · 1 indication

Phase 1 1
NCT07887763A Phase 1 Study to Evaluate Safety, Tolerability, and Drug Levels of BMS-986485 in Healthy Adult ParticipantsHealthy Volunteers
NOT YET_RECRUITING50 Analytics
PHASE1NOT YET_RECRUITING
A Phase 1 Study to Evaluate Safety, Tolerability, and Drug Levels of BMS-986485 in Healthy Adult Participants
Healthy Volunteers
NCT0788776350
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of participants with Treatment Emergent Adverse Events (TEAEs)
Up to approximately Day 29
Number of participants with Serious Adverse Events (SAEs)
Up to approximately Day 29
Number of participants with Vital Signs abnormalities
Up to approximately Day 29
Number of participants with Physical Examination abnormalities
Up to approximately Day 29
Number of Participants with 12-Lead Electrocardiogram (ECG) abnormalities
Up to approximately Day 9
Number of Participants with Holter ECG abnormalities
Up to Day 2

Part A

Number of participants with Clinical Laboratory abnormalities
Up to approximately Day 29
Number of participants with suicidal ideation and behavior assessed by Columbia Suicide Severity Rating Scale (C-SSRS)
Up to Day 9
Time of maximum observed blood concentration (Tmax)
Up to Day 6

Part B

Maximum observed blood concentration (Cmax)
Up to Day 6

Part B

Apparent total body clearance (CL/F)
Up to Day 6

Part B

Apparent volume of distribution during the terminal phase (Vz/F)
Up to Day 6

Part B

Apparent Terminal Phase Half-life (T-HALF)
Up to Day 6

Part B

Geometric mean ratios (GMRs) of Cmax
Up to Day 6

Part B

GMRs of AUC(0-T)
Up to Day 6

Part B

GMRs of AUC(INF)
Up to Day 6

Part B

Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Up to Day 6

Part B

Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
Up to Day 6

Part B

Secondary Endpoints

Time of maximum observed blood concentration (Tmax)
Up to Day 7
Maximum observed blood concentration (Cmax)
Up to Day 7
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Up to Day 7
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part A: SADEXPERIMENTAL -
Part B: Conditional rBAEXPERIMENTAL -

Interventions

NameTypeDescription
BMS-986485DRUGSpecified dose on specified days
BMS-986485 matching placeboOTHERSpecified dose on specified days
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Participants must have body mass index (BMI) range of 18 to 33 kg/m2. Exclusion Criteria: * Participants must not have any significant medical condition (including but, not limited to, neurological, GI, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, end...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 21, 2026NCT07887763NEW_TRIAL: changed
LOWOct 21, 2026NCT07887763NEW_TRIAL: changed
LOWOct 21, 2026NCT07887763NEW_TRIAL: changed

Explore more on BiopharmaWatch

Bristol-Myers Squibb Company (BMY)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with BCompanies A to ZEvery biotech and pharma company we track